Outcome
    Strong Evidence
    Effectiveness 4/5

    Probiotics for Diarrhea Prevention

    Lactobacillus rhamnosus GG is well evidenced for preventing antibiotic-associated and paediatric infectious diarrhoea.

    Overview

    Probiotics are one of the better-evidenced supplement categories for preventing diarrhoea, but the evidence is strain-specific rather than generic. Two organisms carry most of it: Saccharomyces boulardii and Lactobacillus rhamnosus GG, both of which have reduced the incidence of antibiotic-associated diarrhoea in randomised trials and pooled analyses, typically cutting risk by around half when started early. What does not follow is that any product labelled probiotic will do. Strain, dose and timing all determine the result, and trials of unspecified multi-strain blends have often found nothing. Choosing by strain and CFU count is the practical difference between a useful intervention and an expensive placebo.

    Verdict

    Strong yes

    Cochrane-level evidence supports specific strains — notably S. boulardii and L. rhamnosus GG — for preventing antibiotic-associated and traveller's diarrhoea. Benefit does not generalise across all probiotic products.

    How It Works

    Probiotics defend the gut on several fronts at once. They compete with pathogens for adhesion sites and nutrients, produce organic acids and bacteriocins that suppress pathogen growth, and help restore the fermentative capacity that antibiotics strip out — including short-chain fatty acid production that supports colonocyte function and water reabsorption. Saccharomyces boulardii adds a distinct mechanism: as a yeast it is intrinsically resistant to antibacterial antibiotics, so it survives concurrent therapy, and it secretes a protease that degrades Clostridioides difficile toxin A. It also strengthens tight junctions and modulates the local immune response, reducing secretory losses.

    Pathways involved

    Competitive exclusion of pathogens
    Bacteriocin and organic acid production
    Short-chain fatty acid restoration
    Tight junction reinforcement
    Toxin degradation (S. boulardii protease)
    Secretory IgA and mucosal immune modulation

    Dosing & Protocol

    ScenarioDoseFormTiming
    Antibiotic-associated prevention5-20 billion CFU dailyL. rhamnosus GG or S. boulardiiStart with the antibiotic, continue 1-2 weeks after
    S. boulardii specifically250-500 mg twice dailyLyophilised yeastWith or without food
    Traveller's diarrhoea5-10 billion CFU dailyS. boulardii or LGGFrom 2 days before travel
    Paediatric useWeight-based, clinician-directedStrain-specific-
    1. 1

      Choose by strain, not by marketing· Before starting

      Look for L. rhamnosus GG or S. boulardii CNCM I-745 named on the label with a CFU count guaranteed at expiry, not at manufacture.

    2. 2

      Start on day one of antibiotics· Day 1

      Prevention trials began probiotics within 48 hours of the first antibiotic dose. Starting after diarrhoea appears is a different, weaker proposition.

    3. 3

      Separate bacterial strains from the antibiotic· Throughout the course

      Take Lactobacillus doses at least 2 hours apart from the antibiotic. S. boulardii is a yeast and needs no separation.

    4. 4

      Continue past the last antibiotic dose· Weeks 1-2 after

      Keep going for one to two weeks after finishing, since disruption outlasts the course.

    Timing decides the outcome

    The benefit in trials came from starting probiotics alongside the antibiotic, not from reaching for them once symptoms began. Late starts have consistently produced weaker results.

    Evidence

    Cochrane reviews of probiotics for antibiotic-associated diarrhoea, including large paediatric syntheses, report roughly a halving of incidence with the better-studied strains, with number-needed-to-treat figures in the region of one in ten. Separate analyses for C. difficile-associated diarrhoea show a similar direction of effect where baseline risk is high. Heterogeneity is the main limitation: strains, doses and populations differ so much between trials that pooled estimates conceal real variation, and some large pragmatic trials in older inpatients found no benefit at all. No individual trials are linked to this pairing in our database yet, so this reflects the wider literature rather than pair-specific citations.
    Best available evidence
    Cochrane reviews of antibiotic-associated diarrhoea prevention
    Typical effect
    Roughly 50% relative risk reduction with well-studied strains
    Strains with the most support
    S. boulardii CNCM I-745, L. rhamnosus GG
    Where benefit is weakest
    Unspecified blends; frail older inpatients
    Certainty of evidence
    Moderate, with high heterogeneity

    Safety

    Not for the severely immunocompromised

    Case reports document fungaemia with S. boulardii and bacteraemia with Lactobacillus in people with central venous catheters, severe immunosuppression, short bowel syndrome or critical illness. In those settings probiotics should not be used without specialist input.

    Common effects

    Transient bloating and gas in the first days
    Mild abdominal discomfort
    Rare invasive infection in immunocompromised people
    Constipation in some users

    Interactions & Conflicts

    Interacts withSeverityMechanismAction
    Antibacterial antibiotics
    moderate
    		Kill bacterial probiotic strains on contactSeparate Lactobacillus and Bifidobacterium doses by at least 2 hours; S. boulardii is unaffected
    Antifungal agents
    moderate
    		Inactivate S. boulardiiUse a bacterial strain instead during antifungal therapy
    Immunosuppressants
    high
    		Raised risk of invasive infection from live organismsAvoid unless a specialist advises otherwise
    Central venous catheters
    high
    		Route for translocation and line infectionAvoid live probiotics

    References

    1. Guo Q et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhoea. Cochrane Database Syst Rev. 2019
    2. Goldenberg JZ et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.